Hostname: page-component-745bb68f8f-5r2nc Total loading time: 0 Render date: 2025-01-21T23:32:31.436Z Has data issue: false hasContentIssue false
  • English
  • Français

Assessing Health-Related Quality of Life in Patients with Migraine

Published online by Cambridge University Press:  02 December 2014

W.J. Becker
W.J. Becker*
Affiliation:
University of Calgary and Calgary Regional Health Authority, Foothills Hospital, Calgary, Alberta, Canada
*
W J Becker, Foothills Hospital, 12th Floor, Neurology, 1403 – 29th Street NW, Calgary, Alberta T2N 2T9, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background:

The place of health-related quality of life (HRQoL) instruments in clinical research trials and clinical practice as compared to more traditional clinical outcome measures such as headache intensity and frequency is unclear.

Objectives:

To review the current status of HRQoL measurement in migraine.

Methods:

A literature search was done for HRQoL and migraine. Selected articles dealing with migraine and commonly used HRQoL instruments and HRQoL measures used in recent clinical trials were reviewed.

Results:

Several general and migraine specific HRQoLinstruments can detect changes over time in response to at least major changes in migraine therapy. Both also show a correlation with clinical headache features. However, their sensitivity to detect clinically significant changes over time is not clear.

Conclusion:

The SF-36, a general HRQoLmeasure and several migraine-specific HRQoL instruments are useful endpoints for migraine clinical trials. Their role in clinical practice is yet to be established.

Résumé:

RÉSUMÉ:Introduction:

La place des instruments pour mesurer la qualité de vie reliée à la santé (HRQoL) dans les essais cliniques et en pratique, par rapport aux mesures de résultats cliniques plus traditionnels tels l'intensité et la fréquence de la céphalée, n'est pas claire.

Objectifs:

Revoir le statut actuel de la mesure de la HRQoLdans la migraine.

Méthodes:

Une revue de la littérature sur la HRQoL et la migraine a été effectuée. Les articles sélectionnés traitant de la migraine et des instruments d'évaluation de la HRQoL utilisés couramment pour la migraine et des mesures de la HRQoL utilisées dans les essais cliniques récents ont été révisés.

Résultats:

Plusieurs instruments généraux et spécifiques de l'évaluation de la HRQoLdans la migraine peuvent détecter des changements dans le temps, du moins quant à la réponse à des changements majeurs dans le traitement de la migraine. Les deux types d'instruments démontrent une corrélation avec les caractéristiques cliniques de la céphalée. Cependant, leur sensibilité pour détecter des changements cliniquement significatifs dans le temps n'est pas claire.

Conclusion:

Le SF-36, un instrument de mesure général de la HRQoL, et plusieurs instruments de mesure spécifiques de la HRQoL dans la migraine sont utiles dans l'évaluation des résultats au cours des essais cliniques sur la migraine. Leur rôle en pratique clinique n'est pas encore établi.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 29 , Issue S2: A Peer-Reviewed Supplement to the Canadian Journal of Neurological Sciences , 2002 , pp. S16 - S22
Copyright
Copyright © The Canadian Journal of Neurological 2002

References

1. Sheftell, FD, Fox, AW. Acute migraine treatment outcome measures: a clinician’s view. Cephalalgia 2000;20(Suppl 2):14–24.Google Scholar
2. Goadsby, PJ. The scientific basis of medication choice in symptomatic migraine treatment. Can J Neurol Sci 1999;26 (Suppl 3):S20–S26.Google Scholar
3. Becker, WJ. What does it mean to have migraine? Neurology 2000; 55:610–611.Google Scholar
4. Patrick, DL, Hurst, BC, Hughes, J. Further development and testing of the Migraine-Specific Quality of Life (MSQOL) measure. Headache 2000;40:550–560.Google Scholar
5. Wagner, TH, Patrick, DL, Galer, BS, Berzon, RA. A new instrument to assess the long-term quality of life effects from migraine: development and psychometric testing of the MSQOL. Headache 1996;36:484–492.Google Scholar
6. Jhingran, P, Osterhaus, JT, Miller, DW, Lee, JT, Kirchdoerfer, L. Development and validation of the migraine-specific quality of life questionnaire. Headache 1998;38:295–302.Google Scholar
7. Jhingran, P, Davis, SM, LaVange, LM, Miller, DW, Helms, RW. MSQ: Migraine-Specific Quality-of-Life Questionnaire. Pharmaco-economics 1998;13(6):707–717.Google Scholar
8. Martin, BC, Pathak, DS, Sharfman, MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache 2000;40:204–215.Google Scholar
9. Hartmaier, SL, Santanello, NC, Epstein, RS, Silberstein, SD. Development of a brief 24-hour migraine specific quality of life questionnaire. Headache 1995;35:320–329.Google Scholar
10. Santanello, NC, Hartmaier, SL, Epstein, RS, Silberstein, SD. Validation of a new quality of life questionnaire for acute migraine headache. Headache 1995;35:330–337.Google Scholar
11. The WHOQoL Group. The World Health Organisation Quality of Life (WHOQoL) Assessment Instrument. In: Spilker, B (Ed). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd Ed. New York: Raven Press;1995:355–362.Google Scholar
12. Wiebe, S, Derry, PA. Measuring quality of life in epilepsy surgery patients. CJNS 2000;27(Suppl 1):S111–S115.Google Scholar
13. Solomon, GD, Dahlof, CGH. Impact of headache on the headache sufferer. In: Olesen, J, Tfelt-Hansen, P, Welch, KMA (Eds). The Headaches. Second ed, Philadelphia: Lippincott Williams and Williams. 2000.Google Scholar
14. Heywood, J, Bouchar, J, Cortelli, P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. I. Design, methods and clinical findings. Pharmacoeconomics 1997;11(Suppl 1):11–23.Google Scholar
15. Gallagher, RM, Dennish, G, Egilius, LH, Spierings, LH, Chitra, R. A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache 2000;40:119–128.Google Scholar
16. Steiner, TJ. Please don’t hijack “quality of life”. Cephalalgia 1998; 18(4):227–228.Google Scholar
17. Jacobsen, GP, Ramadan, NM, Aggarwal, SK, Newman, CW. The Henry Ford Hospital Headache Disability Inventory (HDI). Neurology 1994;44:837–842.Google Scholar
18. Cavallini, A, Micieli, G, Bussone, G, Rossi, F, Nappi, G. Headache and quality of life. Headache 1995;35:29–35.Google Scholar
19. Passchier, J, Mourik, JC, McKenna, SP, van den Berg, M, Erdman, RAM. Evaluation of the Dutch version of the migraine quality of life instrument (MSQoL) and its application in headache coping. Cephalalgia 2001;21:823–829.Google Scholar
20. Ware, JE. SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center Hospitals Inc., 1997.Google Scholar
21. Terwindt, GM, Ferrari, MD, Tijhuis, M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000;55:624–629.CrossRefGoogle ScholarPubMed
22. Lipton, RB, Hamelsky, SW, Kolodner, KB, Steiner, TJ, Stewart, WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000;55:629–635.Google Scholar
23. Monzon, MJ, Lainez, MJA. Quality of life in migraine and chronic daily headache patients. Cephalalgia 1998;18:638–643.Google Scholar
24. Dahlof, C, Bouchard, J, Cortelli, P, et al. A multinational investigation of the impact of subcutaneous sumatriptan. II. Health-related quality of life. Pharmacoeconomics 1997; 11(Suppl 1):24–34.Google Scholar
25. Solomon, GD, Skobieranda, FG, Genzen, JR. Quality of life assessment among migraine patients treated with sumatriptan. Headache 1995;35:449–454.Google Scholar
26. Santanello, NC, Polis, AB, Hartmaier, SL, et al. Improvement in migraine-specific quality of life in a clinical trial of rizatriptan. Cephalalgia 1997;17:867–872.Google Scholar
27. Vickrey, BG, Berg, AT, Sperling, MR, et al. Relationships between seizure severity and health-related quality of life in refractory localization-related epilepsy. Epilepsia 2000;41(6): 760–764.Google Scholar
28. Birbeck, GL, Kim, S, Hays, RD, Vickrey, BG. Quality of life measures in epilepsy. How well can they detect change over time? Neurology 2000;54:1822–1827.Google Scholar
29. Gijsman, H, Kramer, MS, Sarget, J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997;17:647–651.Google Scholar